CJC-1295 Dosage Guide

CJC-1295 is a 30-amino acid peptide analog of GHRH (growth hormone-releasing hormone) with enhanced stability and extended half-life compared to native GHRH. Two variants exist: CJC-1295 with DAC, which binds to albumin for a half-life of 6–8 days, and CJC-1295 without DAC (Mod GRF 1-29), which has a half-life of approximately 30 minutes.

The DAC variant produces sustained, elevated GH levels, while the no-DAC version produces acute GH pulses that more closely mimic natural physiology. Both variants have been studied in clinical settings for their effects on body composition, sleep quality, and recovery.

Dosing differs significantly between the two variants:

The no-DAC variant is most commonly paired with a GHRP (such as ipamorelin) to amplify GH pulse amplitude, while the DAC variant is used standalone.

CJC-1295 no DAC: Administer 2–3 times daily, ideally upon waking, post-workout, and before bed. Inject on an empty stomach (fast 2 hours before and 30 minutes after). When stacking with ipamorelin, inject both peptides simultaneously.

CJC-1295 with DAC: Inject once weekly (or twice weekly at lower doses). Timing relative to meals is less critical due to the sustained-release mechanism.

Cycling: Standard protocols run 12–16 weeks on, 4 weeks off. Some researchers use the DAC variant in 8-week cycles with 4-week breaks to prevent GH blunting.

• Step 1: Alcohol-swab both vial stoppers.
• Step 2: For a 2 mg vial (no DAC), add 1 mL BAC water for 2 mg/mL (100 mcg per 0.05 mL). For a 5 mg vial (DAC), add 2.5 mL for 2 mg/mL.
• Step 3: Direct the BAC water stream along the glass wall.
• Step 4: Gently swirl to dissolve. Do not shake.
• Step 5: Store at 2–8°C. Use within 21–28 days.

Administer subcutaneously with a 29–31 gauge insulin syringe. The abdominal fat pad is the preferred injection site for consistent absorption.

• Standard doses (100 mcg no DAC / 1 mg DAC): Flushing, transient warmth at injection site, mild water retention, occasional dizziness.
• Higher doses (200 mcg no DAC / 2 mg DAC): Increased water retention, numbness/tingling in extremities, potential CTS-like symptoms, vivid dreams.
• DAC-specific: The sustained GH elevation from DAC variants may cause more pronounced water retention and potential insulin resistance with prolonged use.

CJC-1295 is for research purposes only and is not FDA-approved.

The DAC variant produces supraphysiological GH levels for extended periods, which may carry additional risks including insulin resistance and potential growth factor-related complications. Monitor glucose and IGF-1 levels. Consult a healthcare provider before any research protocol.